Accepted for Publication: December 8, 2013.
Published Online: April 2, 2014. doi:10.1001/jamadermatol.2013.10271.
Study concept and design: J. S. Margolis, D. J. Margolis.
Acquisition of data: J. S. Margolis, Hoffstad, D. J. Margolis.
Analysis and interpretation of data: J. S. Margolis, Abuabara, Bilker, D. J. Margolis.
Drafting of the manuscript: J. S. Margolis, D. J. Margolis.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: J. S. Margolis, Bilker, Hoffstad, D. J. Margolis.
Obtained funding: D. J. Margolis.
Administrative, technical, and material support: D. J. Margolis.
Study supervision: D. J. Margolis.
Conflict of Interest Disclosures: The PEER study is funded by a grant from Valeant Pharmaceuticals, a company that makes pimecrolimus, a drug used to treat AD. The company was notified that the study was submitted for review and publication. The PEER study is an FDA-mandated study as part of the FDA approval process. No other disclosures are reported.
Funding/Support: This study was supported in part by R01-AR0056755 from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS).
Role of the Sponsors: The NIAMS and Valeant Pharmaceuticals had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.